secwatch.observer — SEC 8-K summary
======================================

Issuer:     LENSAR, Inc. (LNSR)
CIK:        0001320350
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0000950170-24-093326
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 1.02, 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LENSAR Reports Q2 2024 Results with 17 ALLY Placements and Terminates Oertli Development Agreement
--------------------------------------------------------------------------------

- Q2 2024 revenue $12.6M, up 5% YoY; net loss $9.0M vs $8.8M loss in Q2 2023.
- Placed 17 ALLY Systems in Q2 2024, highest since launch; total installed base ~330 systems.
- Worldwide procedure volume increased 19% to 42,203 in Q2 2024 from 35,349 in Q2 2023.
- Terminated Development Agreement with Oertli Instrumente AG effective Aug 5, 2024, with no termination penalties.
- Received MDR certification (CE Mark) and Taiwan FDA approval; first EU and SE Asia ALLY systems shipped.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1320350/000095017024093326/0000950170-24-093326-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1320350/000095017024093326/lnsr-20240805.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-093326

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer